Excerpt from Ophthalmology Times blog.
A recent study of cannabinol in in vitro and in vivo glaucoma models, demonstrated encouraging results that may address some of the previous challenges associated with cannabis use and may present a new potential therapeutic intervention in the treatment of glaucoma.
For more than 50 years, cannabis has been the subject of debate for its use as a potential treatment option for glaucoma.
Several studies have shown cannabis’ effect to lower IOP1,2, but there are multiple risks associated with smoking marijuana, such as the short therapeutic window leading to frequent dosing requirements, tachyphylaxis and intoxicating effects from tetrahydrocannabinol (THC), that may counteract any benefit gained.
In addition, the American Academy of Ophthalmology does not support the use of marijuana for the treatment of glaucoma, noting the absence of scientific evidence. However, the mounting scientific evidence of its IOP-lowering effects warrants further research.
A recent study (InMed Pharmaceuticals in collaboration with the University of British Columbia) of cannabinol (CBN), a rare cannabinoid, in in vitro and in vivo glaucoma models, demonstrated encouraging results that may address some of the previous challenges associated with cannabis use and may present a new potential therapeutic intervention in the treatment of glaucoma.
Read article in Ophthalmology Times.
